158 related articles for article (PubMed ID: 23484053)
1. Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.
De Cecco L; Berardi M; Sommariva M; Cataldo A; Canevari S; Mezzanzanica D; Iorio MV; Tagliabue E; Balsari A
PLoS One; 2013; 8(3):e58849. PubMed ID: 23484053
[TBL] [Abstract][Full Text] [Related]
2. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
3. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
4. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
Ruan L; Xie Y; Liu F; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
[TBL] [Abstract][Full Text] [Related]
6. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
7. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
11. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
Arrighetti N; Cossa G; De Cecco L; Stucchi S; Carenini N; Corna E; Gandellini P; Zaffaroni N; Perego P; Gatti L
Toxicol Appl Pharmacol; 2016 Nov; 310():9-19. PubMed ID: 27554045
[TBL] [Abstract][Full Text] [Related]
12. Identification of miRNA/mRNA-Negative Regulation Pairs in Nasopharyngeal Carcinoma.
Liu M; Zhu K; Qian X; Li W
Med Sci Monit; 2016 Jun; 22():2215-34. PubMed ID: 27350400
[TBL] [Abstract][Full Text] [Related]
13. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.
Sommariva M; de Cesare M; Meini A; Cataldo A; Zaffaroni N; Tagliabue E; Balsari A
J Transl Med; 2013 Jan; 11():25. PubMed ID: 23360557
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
17. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of miR-302b-5p expression and molecular mechanism in hepatocellular carcinoma: Findings based on RT-qPCR and in silico analysis.
Wu HY; Cai KT; Ma J; Chen G; Dang YW; Lu HP; Pan SL
Pathol Res Pract; 2019 Jul; 215(7):152424. PubMed ID: 31103408
[TBL] [Abstract][Full Text] [Related]
19. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
Port M; Glaesener S; Ruf C; Riecke A; Bokemeyer C; Meineke V; Honecker F; Abend M
Mol Cancer; 2011 May; 10():52. PubMed ID: 21575166
[TBL] [Abstract][Full Text] [Related]
20. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
